← Back to Patent Explorer
US4229428A Expired / Lapsed US ⏱️ 0.0 years remaining

Galenical form of administration of betahistine and its derivatives

Assignee: Individual
•
Filing: 1979-04-05
•
Granted: 1980-10-21
•
Expires: 1999-04-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract There is provided a medicament in a form having surprising effectiveness against vertigo in Meniere's syndrome. This medicament comprises, as active ingredient, betahistinemethanesulfonate. The medicament further comprises a core of pharmaceutially acceptable thereapeutically inert carrier material having the active ingredient absorbed thereon, said active ingredient being covered with a dialysis membrane said membrane further carrying a second layer of active ingredient which, if desired, is itself absorbed upon a layer of therapeutically inert carrier material and is covered with a further dialysis membrane. There may be utilized a plurality of substantially concentric layers of active material suitably absorbed on the carrier, and covered with a dialysis membrane to provide a long-acting medicament form.

Inventors

  • 👤 Jean S. Cherqui
  • 👤 Alain C. Djiane

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 20:21
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 79 words
A therapeutically useful and pharmacologically acceptable oral depot medicament in the form of substantially uniformally sized spheroidal particles containing 2-methylaminoethyl pyridinemethanesulfonate as the active ingredient thereof comprising (a) an inactive core of pharmaceutically acceptable carrier material; (b) at least two sets of sequential bipartite layers on said core comprising an inner layer of the active ingredient and an outer layer of a dialysis membrane, said membrane being substantially insoluble in neutral or acid environments but soluble above pH 7.
Claim 2
Dependent Claim 79 words
A therapeutically useful and pharmacologically acceptable oral depot medicament in the form of substantially uniformally sized spheroidal particles containing 2-methylaminoethyl pyridinemethanesulfonate as the active ingredient thereof comprising (a) an inactive core of pharmaceutically acceptable carrier material; (b) at least two sets of sequential bipartite layers on said core comprising an inner layer of the active ingredient and an outer layer of a dialysis membrane, said membrane being substantially insoluble in neutral or acid environments but soluble above pH 7.
Claim 3
Dependent Claim 43 words
A medicament in accordance with claim 1 wherein the inner layer of said sequential bipartite layer outwardly of the first dialysis membrane outwardly of the inactive core, additionally comprises pharmaceutically acceptable and pharmaceutically inert carrier material upon which the active ingredient is absorbed.
Claim 4
Dependent Claim 21 words
A medicament in accordance with claim 2 wherein said dialysis material is an anionic polimerizate of methacrylic acid and methacrylic esters.
Claim 5
Dependent Claim 17 words
A medicament in accordance with claim 3 wherein said medicament is further encapsulated in pharmaceutically acceptable capsules.
Claim 6
Dependent Claim 27 words
A method of treating vertigo in patients suffering from Meniere's syndrome which comprises administering to said patients an antivertigo effective amount of a composition of claim 1.
Claim 7
Dependent Claim 21 words
A method of claim 5 which comprises administering to said patients up to 48 mg per day of said active ingredient.

References Cited (Backward Citations)

US3247066A Cited
US3538214A Cited
DE2035301A1 Cited
US3835221A Cited
US3775537A Cited
US3954959A Cited
US4083949A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-10-21 1984-04-21 1984-10-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-10-21 1988-04-21 1988-10-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-10-21 1992-04-21 1992-10-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag